Chiesi Awards Grants to Boost Innovation in Lysosomal Diseases
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative solutions for people living with rare diseases, today announced the...
Tag : lysosomal degradation
Innovent Doses First Patient in Phase 1 Trial of IBI3020 ADC
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology...